Toradol (Ketorolac) is NOT FDA-approved for use in children and should generally be avoided in an 11-year-old
The FDA drug label explicitly states that "ketorolac tromethamine is not indicated for use in pediatric patients" 1. This is a critical contraindication that supersedes other considerations.
Why Ketorolac is Contraindicated in Pediatric Patients
The FDA has not approved ketorolac for pediatric use due to:
- Lack of adequate safety and efficacy data in the pediatric population for FDA approval standards
- Significant bleeding risks, including gastrointestinal bleeding and surgical site hemorrhage
- Renal toxicity concerns, particularly in vulnerable populations
- Serious cardiovascular thrombotic events that may occur even with short-term use 1
Clinical Context and Off-Label Use
Despite the FDA contraindication, ketorolac has been used off-label in pediatric settings, particularly in postoperative pain management. However, this practice comes with important caveats:
Evidence from Pediatric Cardiac Surgery
The most robust pediatric guideline evidence comes from cardiac surgery settings, where ketorolac is used as part of multimodal opioid-sparing regimens 2. However, even in these specialized contexts:
- Ketorolac is associated with acute kidney injury and increased bleeding 2
- It should be used with extreme caution in infants with preexisting renal dysfunction, concomitant aspirin use, or single-ventricle palliation 2
- When used in infants younger than 6 months for 48 hours, it caused significant creatinine increases from baseline 2
Dosing Information from Research (If Used Off-Label)
If a clinician decides to use ketorolac off-label despite FDA contraindication, research suggests:
- 0.5 mg/kg IV every 6 hours is the most commonly studied dose 3, 4, 5
- Maximum single dose: 30 mg (though some use 10 mg maximum) 6
- Maximum duration: 48 hours in pediatric settings 6, 3
- Lower doses (0.5 mg/kg up to 10 mg maximum) may reduce bleeding risk compared to higher ceiling doses 7, 8
Critical Safety Concerns
Bleeding Risk:
- Doses of 0.9-1.0 mg/kg significantly increase primary operative bleeding control (OR = 4.07) and significant bleeding (OR = 2.32) 7
- Lower doses (0.5 mg/kg) show reduced bleeding risk while maintaining analgesic efficacy 7
Renal Effects:
- Monitor renal function closely
- Avoid in patients with preexisting renal dysfunction
- Contraindicated in advanced renal impairment 1
Duration Limits:
- Never exceed 5 days total duration (combined IV and oral) 1
- Most pediatric studies limit use to 48 hours 6, 3
Safer Alternatives for an 11-Year-Old
Instead of ketorolac, consider:
- Ibuprofen: 10 mg/kg PO/IV every 8 hours 6
- Acetaminophen: 15 mg/kg IV loading dose, then 10-15 mg/kg every 6-8 hours 6
- Combination therapy: Acetaminophen + ibuprofen provides excellent analgesia without ketorolac's risks
- Opioids if needed: For severe pain requiring opioid-level analgesia, consider age-appropriate opioid dosing with proper monitoring
Common Pitfalls to Avoid
- Do not assume pediatric dosing is simply weight-based adult dosing - pharmacokinetics differ significantly 3, 4
- Do not use ketorolac for minor or chronic pain - it is only for short-term management of severe acute pain 1
- Do not exceed 48 hours in pediatric patients even though adult labeling allows up to 5 days 6, 3
- Do not use in patients with bleeding disorders, active peptic ulcer disease, or recent GI bleeding 1
The safest recommendation is to use FDA-approved alternatives (ibuprofen, acetaminophen) rather than off-label ketorolac in an 11-year-old child.